Vivani Medical, Inc. announced the appointment of Daniel Bradbury to its board of directors. Bradbury is the former President, Chief Executive Officer, and Director of Amylin Pharmaceuticals, a biopharmaceutical company focused on the development of drug candidates for the treatment of serious metabolic diseases. He served as Amylin?s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7.1B in August 2012.

Before joining Amylin in 1994, he worked in marketing and sales roles for 10 years at SmithKline Beecham Pharmaceuticals. Bradbury serves on the board of directors of Castle Biosciences, Inc. and Equillium, Inc., and several private companies and philanthropic organizations. Bradbury previously served on the board of directors of Biocon Limited, Corcept Therapeutics Inc., Geron Inc., Illumina Inc. and Intercept Pharmaceuticals Inc. He earned a Bachelor of Pharmacy degree from Nottingham University and a Diploma in Management Studies from the University of West London in the United Kingdom.

In addition to his new role as Board Director, Bradbury will serve on the Audit Committee of the Vivani Medical Board.